Write in a clean editor, then format for Pharmacology Research & Perspectives in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Pharmacology Research & Perspectives is a peer-reviewed journal published by Wiley, covering Receptor Mechanisms and Signaling, Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Pharmacology Research & Perspectives 12 (3): 45–58.
Formats any DOI in Pharmacology Research & Perspectives style. No sign-up. |
| Publishes research in | Receptor Mechanisms and Signaling Pharmacogenetics and Drug Metabolism Drug Transport and Resistance Mechanisms Neuroscience and Neuropharmacology Research Antibiotics Pharmacokinetics and Efficacy |
| ISSN | 2052-1707 |
| Citation impact (2-yr) | 3.18 |
| h-index | 60 |
| i10-index | 702 |
| Total citations | 24,829 |
| Article processing charge | $2,500 |
| Open access | Yes |
| Top institutions publishing here | University of Nottingham |
| Journal website | bpspubs.onlinelibrary.wiley.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Combination therapies exploit the chances for better efficacy, decreased toxicity, and reduced development of drug resistance and owing to these advantages, have become a standard for the treatment of several diseases and continue to represent a promising approach in indications of unmet medical need. In this context, studying the effects of a combination of drugs…
Emerging viruses such as HIV, dengue, influenza A, SARS coronavirus, Ebola, and other viruses pose a significant threat to human health. Majority of these viruses are responsible for the outbreaks of pathogenic lethal infections. To date, there are no effective therapeutic strategies available for the prophylaxis and treatment of these infections. Chloroquine analogs have been…
Monoclonal antibodies (mAbs) have emerged as a major class of therapeutic agents on the market. To date, approximately 80 mAbs have been granted marketing approval. In 2018, 12 new mAbs were approved by the FDA, representing 20% of the total number of approved drugs. The majority of mAb therapeutics are for oncological and immunological/infectious diseases,…
The gabapentinoid drugs gabapentin and pregabalin are key front-line therapies for various neuropathies of peripheral and central origin. Originally designed as analogs of GABA, the gabapentinoids bind to the α 2 δ-1 and α 2 δ-2 auxiliary subunits of calcium channels, though only the former has been implicated in the development of neuropathy in animal…
Abstract Cannabidiol (CBD) is the second most abundant component of the Cannabis plant and is known to have effects distinct from Δ 9 ‐tetrahydrocannabinol (THC). Many studies that examined the behavioral effects of CBD concluded that it lacks the psychotomimetic effects attributed to THC. However, CBD was shown to have a broad spectrum of effects…
